Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10162483 | 0.91 | POLB (0.47) | SMN1; SMN2POLBTHRBTP53LMNA | |
| SCHEMBL8253247 | 0.90 | POLB (0.46) | SMN1; SMN2POLBTHRBTP53LMNA | |
| SCHEMBL8256456 | 0.90 | KMT2A (0.48) | SMN1; SMN2POLBTHRBTP53LMNA | |
| SCHEMBL10162440 | 0.87 | POLB (0.45) | SMN1; SMN2POLBTHRBTP53LMNA | |
| SCHEMBL10162361 | 0.86 | AKT3 (0.43) | SMN1; SMN2POLBTHRBTP53LMNA | |
| SCHEMBL10165685 | 0.86 | MAPK1 (0.46) | CNR2 | |
| SCHEMBL10165648 | 0.83 | EGLN1 (0.46) | SMN1; SMN2POLBTHRBL3MBTL1ALDH1A1 | |
| SCHEMBL10162460 | 0.82 | MMP13 (0.45) | L3MBTL1 | |
| SCHEMBL10162203 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2POLBTHRBTP53LMNA | |
| SCHEMBL10162464 | 0.81 | MMP13 (0.53) | SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | SMN1; SMN2 4594/4885POLB 1285/4885THRB 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.